ClinicalTrials.gg
RecruitingNCT06895070NIHP-CAP-001Updated Mar 18, 2026

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

An interventional study of Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT) in Heart Transplant, Heart Failure and Transplant; Failure, Heart, sponsored by XVIVO Perfusion. Recruiting at 14 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by XVIVO Perfusion · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Planned enrollment
817th of 1,602
60 · median 66
Started
2025
with 107 others
No phase
887 of 2,159
159 open now
Primary completion
2026-05
later than 77 of 438 live
Registered
1,996th of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 817th largest by planned enrollment of the 1,602 interventional ones that give a count, is one of 108 that started in 2025, is one of 887 with no phase, reaches primary completion later than 77 of the 438 other live ones, and was the 1,996th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if Non-Ischemic Heart Preservation (NIHP) of extended criteria donor hearts using the XVIVO Heart Preservation System (XHPS) is a safe and effective way to preserve and transport hearts for transplantation.

Read the detailed description

This is a continuation of the PRESERVE IDE trial to provide additional data evaluating the safety and effectiveness of the XVIVO Heart Assist Transport System. The PRESERVE Continued Access Protocol (CAP) will utilize the XHAT System to preserve donor hearts that may not meet current standard donor heart acceptance criteria with the intention of these hearts being transplanted. The CAP has been implemented to allow patients and physicians access to the XHAT System while a Post-Market Approval (PMA) application is being submitted and reviewed.

03

Conditions studied

  • Heart Transplant
  • Heart Failure
  • Transplant; Failure, Heart

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, a recipient must meet all the following criteria:

  1. Age ³18 years.
  2. Signed form (ICF).
  3. Listed for heart transplantation.

Exclusion criteria

Exclusion Criteria Recipient:

  1. Previous solid organ or bone marrow transplantation.
  2. Requires a multi-organ transplant.
  3. Subject is enrolled and ongoing in another pharmaceutical or medical device clinical trial (Exception: observational studies are permitted).
  4. Subject is on mechanical circulatory support pre-transplant other than durable LVAD, Impella or intra-aortic balloon pump (IABP).
  5. History of complex congenital heart disease ie: single ventricle physiology (per Investigator's discretion and XVIVO review).
  6. Subject on renal replacement therapy/dialysis.
  7. Ventilator dependence (subject is intubated at time of transplant/unable to provide consent or re-affirmation of consent).
  8. Sensitized participants meeting any of the following:

    • Participant with calculated Panel Reactive Antibody (cPRA) greater than 50%
    • Participant undergoing any desensitization treatment (also with cPRA less than 50%)
    • Participant with a positive prospective crossmatch and/or a positive virtual cross match

Donor Inclusion Criteria:

To be eligible to participate in this study, the donor heart must meet the following criteria:

  1. Estimated Cross Clamp Time ≥4 hours OR
  2. Estimated Cross Clamp ≥ 2 hours AND

Any one or more of the following:

  • Age ≥50 years
  • 40% - 50% at time of provisional acceptance. (Refer to section 6.3.4 for definition of provisional acceptance).
  • Down-time ≥20 minutes
  • Hypertrophy septal thickness >12 - ≤16mm
  • Angiographic luminal irregularities with no significant CAD OR 1) Donation after Circulatory Death (DCD)

Donor Exclusion Criteria:

Donor hearts that meet any of the following criteria will be excluded from transplantation in this study:

  1. Unstable hemodynamics requiring high-dose inotropic support.
  2. Significantly abnormal coronary angiogram defined as CAD > 50% stenosis of one or more vessels or if the donor heart exhibits any contusions, structural damage, gross abnormalities, or palpable CAD on final examination.
  3. Moderate to severe cardiac valve pathology.
  4. Investigator's clinical decision to exclude from trial.
  5. Previous sternotomy.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Device: Preservation of hearts for transplant.

    Device: Preservation of hearts for transplant.

    Device: Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)

Interventions

  • DeviceNon-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Assist Transport (XHAT)

    Study donor hearts meeting extended criteria are preserved via Non-Ischemic Heart Preservation (NIHP) using the XVIVO Heart Preservation System (XHPS)

06

What researchers measure

Primary outcomes

  1. The percentage of patient treatment success rate

    The percentage of patient treatment success rate at 30-days post transplantation. The treatment success is defined as freedom from treatment failure.

    Time frame: 30 days post transplantation

  2. The percentage of patient survival

    The percentage of patient survival at 365 days from the date of transplant. The long-term safety success is defined as survival.

    Time frame: Post-operative Day 365.

07

Study locations

14 of 14 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for May 2026, 10 months after the start.

Of 236 industry-sponsored interventional studies with no phase under Heart Failure, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 61. This study's planned 10 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2025
First posted
Mar 26, 2025
StartActual
Jul 10, 2025
Primary completionEst.
May 2026
CompletionEst.
May 2031
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06895070
Lead sponsor
XVIVO Perfusion
Responsible party
Sponsor
First posted
Mar 26, 2025
Start date
Jul 10, 2025
Primary completion
May 2026 (estimated)
Completion
May 2031 (estimated)
Last update
Mar 18, 2026

Study contacts

Amanda Carpenter
Contact
Amanda.Carpenter@xvivogroup.com
617-283-8332
Sarah Lowe
study director · XVIVO Perfusion

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion